nitroglycerin has been researched along with Coronary Restenosis in 12 studies
Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.
nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.
nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "ST-segment elevation is frequently induced by dobutamine in patients with a recent myocardial infarction and may represent dyskinesia of the infarcted region or myocardial viability and ischaemia." | 7.72 | Dobutamine-induced ST-segment elevation associated with a biphasic response of wall motion in patients with a recent myocardial infarction is caused by myocardial ischaemia and is abolished by revascularization of the infarct-related artery. ( Canosi, U; Klersy, C; Lanzarini, L; Previtali, M; Scelsi, L; Sebastiani, R, 2003) |
| "ST-segment elevation is frequently induced by dobutamine in patients with a recent myocardial infarction and may represent dyskinesia of the infarcted region or myocardial viability and ischaemia." | 3.72 | Dobutamine-induced ST-segment elevation associated with a biphasic response of wall motion in patients with a recent myocardial infarction is caused by myocardial ischaemia and is abolished by revascularization of the infarct-related artery. ( Canosi, U; Klersy, C; Lanzarini, L; Previtali, M; Scelsi, L; Sebastiani, R, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (83.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sabaté, M | 1 |
| Alfonso, F | 1 |
| Cequier, A | 1 |
| Romaní, S | 1 |
| Bordes, P | 1 |
| Serra, A | 1 |
| Iñiguez, A | 1 |
| Salinas, P | 1 |
| García Del Blanco, B | 1 |
| Goicolea, J | 1 |
| Hernández-Antolín, R | 1 |
| Cuesta, J | 1 |
| Gómez-Hospital, JA | 1 |
| Ortega-Paz, L | 1 |
| Gomez-Lara, J | 1 |
| Brugaletta, S | 1 |
| Roa-Garrido, J | 1 |
| Gomez-Menchero, AE | 1 |
| El Amrawy, AM | 1 |
| Cardenal-Piris, R | 1 |
| Camacho-Freire, S | 1 |
| Diaz-Fernandez, JF | 1 |
| Farhan, S | 1 |
| Hemetsberger, R | 1 |
| Matiasek, J | 1 |
| Strehblow, C | 1 |
| Pavo, N | 1 |
| Khorsand, A | 1 |
| Petneházy, O | 1 |
| Petrási, Z | 1 |
| Kaider, A | 1 |
| Glogar, D | 1 |
| Huber, K | 1 |
| Gyöngyösi, M | 1 |
| Akcakoyun, M | 1 |
| Kargin, R | 1 |
| Tanalp, AC | 1 |
| Pala, S | 1 |
| Ozveren, O | 1 |
| Akcay, M | 1 |
| Barutcu, I | 1 |
| Kirma, C | 1 |
| Sharma, AK | 1 |
| Ajani, AE | 1 |
| Garg, N | 1 |
| GebreEyesus, A | 1 |
| Varghese, J | 1 |
| Pinnow, E | 1 |
| Waksman, R | 1 |
| Pichard, AD | 1 |
| Lindsay, J | 1 |
| Lanzarini, L | 1 |
| Scelsi, L | 1 |
| Canosi, U | 1 |
| Klersy, C | 1 |
| Sebastiani, R | 1 |
| Previtali, M | 1 |
| Togni, M | 2 |
| Windecker, S | 2 |
| Wenaweser, P | 2 |
| Tueller, D | 1 |
| Kaisaier, A | 1 |
| Maier, W | 1 |
| Meier, B | 2 |
| Hess, OM | 2 |
| Tepliakov, AT | 1 |
| Rybal'chenko, EV | 1 |
| Krylov, AL | 1 |
| Stepacheva, TA | 1 |
| Vesnina, ZhV | 1 |
| D'iakova, ML | 1 |
| Hofma, SH | 1 |
| van der Giessen, WJ | 1 |
| van Dalen, BM | 1 |
| Lemos, PA | 1 |
| McFadden, EP | 1 |
| Sianos, G | 1 |
| Ligthart, JM | 1 |
| van Essen, D | 1 |
| de Feyter, PJ | 1 |
| Serruys, PW | 1 |
| Thanyasiri, P | 1 |
| Kathir, K | 1 |
| Celermajer, DS | 1 |
| Adams, MR | 1 |
| Räber, L | 1 |
| Cocchia, R | 1 |
| Cook, S | 1 |
| Wei, W | 1 |
| Floten, HS | 1 |
| He, GW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MAGnesium-based Bioresorbable Scaffold and Vasomotor Function in Patients With Acute ST Segment Elevation Myocardial Infarction[NCT03234348] | Phase 3 | 151 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.[NCT00552669] | Phase 4 | 200 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions. (NCT00552669)
Timeframe: Follow up will be conducted by the coordinating Center at 18 months of follow up
| Intervention | US dollars (Mean) |
|---|---|
| Oral Sirolimus + Bare Metal Stent | 5483 |
| Drug Eluting Stents | 7658.2 |
Efficacy end point was TVR as revasacularization of the treated vessel. (NCT00552669)
Timeframe: 18 months
| Intervention | vessels (Number) |
|---|---|
| Oral Sirolimus + Bare Metal Stent | 14 |
| Drug Eluting Stents | 15 |
Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke. (NCT00552669)
Timeframe: 18 Months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| MACCE | Death | Acute Myocardial Infarction | Stroke | |
| Drug Eluting Stents | 15 | 7 | 9 | 1 |
| Oral Sirolimus + Bare Metal Stent | 9 | 3 | 6 | 0 |
2 trials available for nitroglycerin and Coronary Restenosis
| Article | Year |
|---|---|
Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial.
Topics: Absorbable Implants; Acetylcholine; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coro | 2019 |
Interaction between vasodilators and vasopressin in internal mammary artery and clinical significance.
Topics: Arginine Vasopressin; Coronary Artery Bypass; Coronary Restenosis; Culture Techniques; Diltiazem; Do | 2002 |
10 other studies available for nitroglycerin and Coronary Restenosis
| Article | Year |
|---|---|
Optical Coherence Tomography Image of Coronary Spasm in a Bioresorbable Vascular Scaffold.
Topics: Absorbable Implants; Acute Coronary Syndrome; Coronary Angiography; Coronary Restenosis; Coronary St | 2018 |
Implantation of paclitaxel-eluting stent impairs the vascular compliance of arteries in porcine coronary stenting model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Coronary Restenosis; Coronary Stenosis; Coronary Vessels | 2009 |
Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events and restenosis in patients undergoing coronary stent implantation: a prospective study.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Flow Velocity; Brachial Artery; Cardiovascular Diseases; | 2008 |
Percutaneous interventions in radial artery grafts: clinical and angiographic outcomes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enz | 2003 |
Dobutamine-induced ST-segment elevation associated with a biphasic response of wall motion in patients with a recent myocardial infarction is caused by myocardial ischaemia and is abolished by revascularization of the infarct-related artery.
Topics: Adrenergic beta-Agonists; Aged; Angioplasty, Balloon, Coronary; Biomarkers; Coronary Angiography; Co | 2003 |
Deleterious effect of coronary brachytherapy on vasomotor response to exercise.
Topics: Aged; Angioplasty, Balloon; Brachytherapy; Coronary Angiography; Coronary Restenosis; Coronary Steno | 2004 |
[An experience of the use of stenting for recurrence of myocardial ischemia after coronary artery bypass grafting].
Topics: Coronary Angiography; Coronary Artery Bypass; Coronary Restenosis; Exercise Test; Female; Humans; Hy | 2005 |
Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation.
Topics: Aged; Coronary Angiography; Coronary Restenosis; Coronary Vasospasm; Diabetes Mellitus, Type 2; Diab | 2006 |
Endothelial dysfunction and restenosis following percutaneous coronary intervention.
Topics: Acetylcholine; Aged; Angioplasty, Balloon, Coronary; Case-Control Studies; Coronary Angiography; Cor | 2007 |
Local vascular dysfunction after coronary paclitaxel-eluting stent implantation.
Topics: Administration, Sublingual; Antineoplastic Agents, Phytogenic; Blood Vessel Prosthesis Implantation; | 2007 |